prod:prod_dcx-login
Xpert® Xpress CoV-2 plus
Designed with 3 gene targets for a rapid, robust detection of SARS-CoV-2
Sign in or create a MyCepheid account to add items to cart
Test pack size(s)
10 Tests
XP3SARS-COV2-10
Qty
Unit price
Subtotal
USD
Product is not available for purchase in your region.
Collection devices
Copan 305CN (Nasopharyngeal Swab) (Pack of 50)
305C
Qty
Unit price
Subtotal
USD
Product is not available for purchase in your region.
Copan 346N (Nasal Swab) (Pack of 50)
346C
Qty
Unit price
Subtotal
USD
Product is not available for purchase in your region.
Total
{{currency}}
0
Error adding items to cart. If this error persists, please contact Digital Support
The Need
- SARS-CoV-2 infections are associated with increased morbidity, mortality, cost and pose an ever-present threat to public health globally.1,2
- SARS-CoV-2 variants continue to emerge, resulting in the risk of new surge cases and death.2
- Testing required to identify the breakthrough infections and informing patient care, especially for the high-risk population.3
1 WHO Coronavirus (COVID-19) Dashboard – Last accessed 22nd Sep 2023
2 https://news.un.org/en/story/2023/05/1136367
3 Peeling RW, Heymann DL, Teo YY, Garcia PJ. Diagnostics for COVID-19: moving from pandemic response to control. Lancet. 2022 Feb 19;399(10326):757-768. doi: 10.1016/
S0140-6736(21)02346-1. Epub 2021 Dec 20. PMID: 34942102; PMCID: PMC8687671
2 https://news.un.org/en/story/2023/05/1136367
3 Peeling RW, Heymann DL, Teo YY, Garcia PJ. Diagnostics for COVID-19: moving from pandemic response to control. Lancet. 2022 Feb 19;399(10326):757-768. doi: 10.1016/
S0140-6736(21)02346-1. Epub 2021 Dec 20. PMID: 34942102; PMCID: PMC8687671
The Solution
The Xpert Xpress CoV-2 plus test is a rapid, real-time PCR test intended for the qualitative detection of nucleic acid from SARS-CoV-2 in nasopharyngeal swab or anterior nasal swab specimens from individuals suspected of COVID-19 by their healthcare provider, as well as anterior nasal swab specimens from any individual, including from individuals without symptoms or other reasons to suspect COVID-19
The Xpert Xpress CoV-2 plus test provides:
The Xpert Xpress CoV-2 plus test provides:
- Fast and accurate results in as early as 20 minutes*
- Three gene targets for the detection of SARS-CoV-2, providing target redundancy to mitigate potential impact of genetic mutation
- Rapid sample-to-answer testing with actionable results and minimal hands-on-time
* With early assay termination for positives, otherwise, the full test runtime is 30 minutes.
CE-IVD. In Vitro Diagnostic Medical Device. May not be available in all countries
CE-IVD. In Vitro Diagnostic Medical Device. May not be available in all countries
The Impact
- Support clinicians with broader coverage for SARS-CoV-2 variants with a three-gene target design.
- Rapid PCR workflows can reduce time to result, isolation times, and total costs while optimizing capacity. 5
- Enable patients to receive timely and appropriate treatment.4
4 Shah MM, Joyce B, Plumb ID, et al. Paxlovid Associated with Decreased Hospitalization Rate Among Adults with COVID-19 — United States, April–September 2022. MMWR
Morb Mortal Wkly Rep 2022;71:1531–1537.
5 Fistera D, Kikull K, Risse J, Herrmann A, Brachmann M, Kill C. Point-of-care PCR testing of SARS-CoV-2 in the emergency department: Influence on workflow and efficiency.
PLoS One. 2023 Aug 3;18(8) https://pubmed.ncbi.nlm.nih.gov/37535577/
Morb Mortal Wkly Rep 2022;71:1531–1537.
5 Fistera D, Kikull K, Risse J, Herrmann A, Brachmann M, Kill C. Point-of-care PCR testing of SARS-CoV-2 in the emergency department: Influence on workflow and efficiency.
PLoS One. 2023 Aug 3;18(8) https://pubmed.ncbi.nlm.nih.gov/37535577/
Product Resources
Package Inserts & MSDS
Technical Documentation
ADF Files
Frequently Asked Questions
Cepheid developed the Xpert® Xpress CoV-2 plus test with several enhancements compared to the Xpert® Xpress SARS-CoV-2. Key enhancements include:
- The addition of a 3rd gene target for SARS-CoV-2 (RdRP now included in addition to E and N2), to be more robust against mutations
- Improved Time to Result (TTR) at about 30 minutes
- Expansion of on-label transport media options to include the addition of eNAT®
Sample Types:
GeneXpert Dx and Infinity Systems: Nasopharyngeal swab and anterior nasal swab in 3mL of viral transport media (UTM/VTM), 3mL of Saline, or 2mL of eNAT, from individuals meeting COVID-19 clinical and/or epidemiological criteria, as well as individuals without symptoms or other reasons to suspect COVID-19 infection.
Viral transport media are available from several commercial vendors who may use the terminology VTM (Viral Transport Medium) or UTM (Universal Transport Medium). Any brand meeting the guidelines for VTM/UTM can be used. UTM, VTM, Saline, and eNAT are on label.
- SARS-Related Coronavirus 2 (SARS-CoV-2) External Run Control, Catalog# NATSARS(COV2)-ERC
- SARS Associated Coronavirus 2 (SARS-CoV-2) Negative Control, Catalog# NATSARS(COV2)-NEG
These are described in the “materials available but not provided” section of the package insert as the recommended source for external controls. Please consult with Cepheid’s Technical Support team to inquire about other commercial sources for QC material.
In an effort to reduce our environmental footprint, Cepheid is moving towards CD-less products. The Package Inserts, ADFs and ADF import instructions for the Xpert® Xpress CoV-2 plus test are available for download on this website (see above). For customers who prefer to obtain the ADFs in a CD, please fill out the CD ADF request using the following link: